MX2021010744A - Metodos para el tratamiento de la perimenopausia y la menopausia. - Google Patents

Metodos para el tratamiento de la perimenopausia y la menopausia.

Info

Publication number
MX2021010744A
MX2021010744A MX2021010744A MX2021010744A MX2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A MX 2021010744 A MX2021010744 A MX 2021010744A
Authority
MX
Mexico
Prior art keywords
perimenopause
menopause
methods
treatment
pregnan
Prior art date
Application number
MX2021010744A
Other languages
English (en)
Inventor
Carlos Loya
Nicholas Demartinis
Gabriel Belfort
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2021010744A publication Critical patent/MX2021010744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Abstract

La invención se refiere a métodos para tratar los síntomas de la perimenopausia o la menopausia utilizando moduladores alostéricos positivos del receptor del ácido y-aminobutírico tipo A (GABA-A PAM), que incluye 3a-hidroxi-38-metoximetil- 21-(1'-imidazolil)-5a -pregnan-20-ona y sus sales.
MX2021010744A 2019-03-04 2020-03-04 Metodos para el tratamiento de la perimenopausia y la menopausia. MX2021010744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813498P 2019-03-04 2019-03-04
PCT/US2020/020938 WO2020180955A1 (en) 2019-03-04 2020-03-04 Methods for the treatment of perimenopause and menopause

Publications (1)

Publication Number Publication Date
MX2021010744A true MX2021010744A (es) 2022-01-18

Family

ID=72337303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010744A MX2021010744A (es) 2019-03-04 2020-03-04 Metodos para el tratamiento de la perimenopausia y la menopausia.

Country Status (8)

Country Link
US (1) US20220125803A1 (es)
EP (1) EP3934655A4 (es)
JP (1) JP2022524505A (es)
CN (1) CN113891715A (es)
AU (1) AU2020231506A1 (es)
CA (1) CA3132728A1 (es)
MX (1) MX2021010744A (es)
WO (1) WO2020180955A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024507638A (ja) * 2021-01-28 2024-02-21 セージ セラピューティクス， インコーポレイテッド 性機能障害処置のための神経刺激性ステロイドの使用
WO2022177718A1 (en) * 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007600A2 (en) * 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
ES2344313T3 (es) * 2005-06-09 2010-08-24 Euro-Celtique S.A. Composiciones farmaceuticas de un esteroide neuroactivo y usos de las mismas.
NZ731034A (en) * 2014-10-16 2024-02-23 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US10391105B2 (en) * 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens

Also Published As

Publication number Publication date
CN113891715A (zh) 2022-01-04
EP3934655A1 (en) 2022-01-12
CA3132728A1 (en) 2020-09-10
EP3934655A4 (en) 2022-12-21
JP2022524505A (ja) 2022-05-06
WO2020180955A1 (en) 2020-09-10
AU2020231506A1 (en) 2021-09-30
US20220125803A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
MX2021010744A (es) Metodos para el tratamiento de la perimenopausia y la menopausia.
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP2661175A4 (en) COMBINATION STEROID AND GLUCOCORTICOID RECEPTORANT AGONIST THERAPY
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
MX2022004203A (es) Profarmacos de inhibidores de mieloperoxidasa.
MX2022011888A (es) Tratamiento de trastornos respiratorios.
BR112022017998A2 (pt) Formulações de liberação controlada compreendendo drotaverina ou sal da mesma
AU2014352875A8 (en) Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
ZA202203367B (en) Treatment of menstrual cycle-induced symptoms
CL2022001167A1 (es) Tratamiento de trastornos hepáticos